Navigation Links
Slow-release 'jelly' delivers drugs better
Date:1/28/2013

DURHAM, NC -- Duke University biomedical engineers have developed a new delivery system that overcomes the shortcomings of a promising class of peptide drugs very small proteins for treating diseases such as diabetes and cancer.

There are more than 40 peptide drugs approved for use in humans and more than 650 are being tested in clinical studies. One example is the hormone insulin, a peptide that regulates the metabolism of carbohydrates in the body and is used as a drug to treat diabetes.

Despite their effectiveness, peptide drugs cannot achieve their full potential for a number of reasons. They are rapidly degraded in the blood stream and they are cleared rapidly from the body, which requires multiple, frequent injections. Because of this, peptide concentrations in the blood can rise precipitously just after injection and fall dramatically soon thereafter, causing unwanted side effects for patients.

One popular method to solve this problem involves loading peptide drugs into polymer microspheres that are injected under the skin and slowly degrade to release the peptide drug. Microsphere-release technology has proven useful, but has many issues related to its manufacture and ease of patient use, the researchers said.

"We wanted to know if we could create a system that does what the polymer microspheres do, but gets rid of the microspheres and is more patient-friendly," said Ashutosh Chilkoti, Theo Pilkington professor of biomedical engineering in Duke's Pratt School of Engineering.

The new approach involves making a "fusion protein" that consists of multiple copies of a peptide drug fused to a polymer which is sensitive to body heat. The fusion molecule is a liquid in a syringe but transforms into a "jelly" when injected under the skin. Enzymes in the skin then attack the injected drug depot and liberate copies of the peptide, providing a constant and controllable release of the drug over time.

Miriam Amiram, former Chilkoti graduate student and first author on the paper, dubbed the new delivery system POD, for protease-operated depot.

In the latest experiments, published on-line in the journal Proceedings of the National Academy of Sciences, the researchers fused glucagon-like peptide-1 (GLP-1), a hormone that regulates the release of insulin, with a genetically engineered heat-sensitive polymer to create the POD.

"Remarkably, a single injection of the GLP-1 POD was able to reduce blood glucose levels in mice for up to five days, which is 120 times longer than an injection of the peptide alone," Chilkoti said. "For a patient with type 2 diabetes, it would be much more desirable to inject such a drug once a week or once a month rather than once or twice a day.

"Additionally, this approach avoids the peaks and valleys of drug concentrations that these patients often experience," Chilkoti said.

Unlike peptide-loaded microspheres, PODs are also easy to manufacture, because the peptide drug and the heat-sensitive polymer are all made of amino acids. They can be built as one long stretch of amino acids by engineered bacteria.

"This new delivery system provides the first entirely genetically encoded alternative to peptide drug encapsulation for sustained delivery of peptide drugs," Chilkoti said.


'/>"/>

Contact: Richard Merritt
richard.merritt@duke.edu
919-660-8414
Duke University
Source:Eurekalert

Related biology technology :

1. Jellyfish inspires latest ocean-powered robot
2. CEM President and CEO Delivers Commencement Address at the 2012 University of Texas at Austin Chemistry and Biochemistry Department Graduation
3. Specialty Chemical Forum 2012 Kicks Off in Houston; AkzoNobels Frank Sherman Delivers Keynote Address
4. Novel nanotherapeutic delivers clot-busting drugs directly to obstructed blood vessels
5. New technology delivers sustained release of drugs for up to 6 months
6. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
7. FDAs Oncologic Drugs Advisory Committee to Review Resubmitted Pixantrone New Drug Application on February 9, 2012
8. DFH Pharma to Collaborate With National Cancer Institute to Develop Second-Generation HIV Maturation Inhibitor Drugs
9. New drugs show promise for preventing absence seizures in children: UBC research
10. Islet Sciences Announces DiaKine Therapeutics Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection
11. Researchers reveal why some pain drugs become less effective over time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s Medical ... place on 7th and 8th June 2018 in San Francisco, CA. The Summit brings ... well as several distinguished CEOs, board directors and government officials from around the world ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the ... for Excellence in Volunteer Experience from US2020. , US2020’s mission is to change ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, ... Hack the Genome hackathon at Microsoft,s headquarters ... two-day competition will focus on developing health and wellness ... Hack the Genome is the first ... tremendous. The world,s largest companies in the genomics, tech ...
Breaking Biology News(10 mins):